Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Drugs In Development, 2024 report and make more profitable business decisions.
Multiple system atrophy (MSA), or Shy-Drager syndrome, is a neurological disorder that impairs the body’s involuntary functions (blood pressure, heart rate, bladder function, and digestion). Symptoms include rigid muscles, bradykinesia, tremors, dysarthria, dysphagia, constipation, incontinence, and irregular heartbeat. Treatment is aimed at relieving symptoms with anti-Parkinson’s medications.
The Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) drugs in development market research report provide comprehensive information on the therapeutics under development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 47 molecules, with 46 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AC Immune SAAllyx Therapeutics Inc
Alterity Therapeutics Ltd
Aprinoia Therapeutics Inc
Arvinas Inc
Asha Therapeutics LLC
Asklepios BioPharmaceutical Inc
AstraZeneca Plc
Biohaven Ltd
BRI Pharma Co Ltd
Coave Therapeutics
Corestemchemon Inc
Cytora Ltd
Denali Therapeutics Inc
Enterin Inc
Genmab AS
Inhibikase Therapeutics Inc
IntraBio Ltd
Ionis Pharmaceuticals Inc
iRegene Therapeutics Co Ltd
Kainos Medicine Inc
MitoDys Therapeutics Ltd
Neuramedy Co Ltd
NysnoBio LLC
Ono Pharmaceutical Co Ltd
Pangolin Therapeutics Inc
Parkure Ltd
PharmaKure Ltd
ProMIS Neurosciences Inc
Stealth BioTherapeutics Inc.
Syngle Therapeutics BV
Teva Pharmaceutical Industries Ltd
The University of Tokyo Hospital
Vaxxinity Inc
Yoda Pharmaceuticals Inc
Zambon Co SpA
Table of Contents
Table
Figures
Frequently asked questions